

ZESTAGEN, A MONOCLONAL ANTIBODY COMPANY IN ONCOLOGY

Zestagen S.A. is a pre-clinical stage biotechnology company developing a first-in-class biologic (ZG101) for the treatment of cancer. ZG101 is a mouse monoclonal antibody that binds a unique extracellular form of HSP90 (eHSP90) secreted only by cancer cells. ZG101 does not bind normal cells. We predict that the humanized antibody will exhibit a highly favorable clinical side-effect profile that will strongly differentiate it from competing small molecule HSP90 inhibitors that block the target in all cells. ZSG102 is a partially human ZSG101 retaining full functionality (target binding, efficacy).

Zestagen is seeking \$7M in series A capital (milestone-driven) to take our lead antibody through to clinical Phase I within 36 months from funding.

ZESTAGEN AT A GLANCE

**Swiss VC Board-recommended #1 biotech startup to invest
(of 7 biotechs out of 50 tech start ups; Bilan magazine, Feb 13)**



THERAPEUTIC TARGET

- Extracellular Heat Shock Protein-90 (eHSP90)
- eHSP90 is expressed at the surface of cancer cells but not of normal adult cells
- Preliminary data establish eHSP90 as a metastasis-promoting agent

ANTIBODIES

- Single light chain binds antigen; much smaller than traditional monoclonals; successfully expressed in bacteria and purified to >95% homogeneity
- Selective binding to eHSP90; no Ab internalization and hence low predicted toxicity against intracellular HSP90 in normal tissues
- Potent anti-tumor activity in vivo (breast cancer & melanoma animal models)
- 36 months to enter Phase I

INTELLECTUAL PROPERTY

- Patent portfolio matured to PCT (WO2012/041863) –Issued US patent; Portfolio managed by Saul Ewing, Boston

PEOPLE

- International team with strong experience in cancer drug development
- Scientific Advisory Board includes Prof. Bruce Zetter (Harvard Medical School & Children's Hospital, Boston) and Prof. Lia Patsavoudi (Pasteur Institute), the eHSP90 field pioneer

MANAGEMENT

Dr. Nassos Alevizopoulos, CEO
+41-21-588-0621
nalevizo@zestagen.com

Martin Austin, Chairman
+41-61-283-4460
mcaustin@ventac-partners.com

Zestagen SA
4, rue de la Corniche
1066, Epalinges, Switzerland
www.zestagen.com